This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Jun 2012

TaiGen & ZMC Sign Agreement for Antibiotic Nemonoxacin

TaiGen Biotechnology and Zhejiang Medicine Company have agreed terms for the broad-spectrum antibiotic nemonoxacin.

TaiGen Biotechnology and Chinese pharmaceutical firm Zhejiang Medicine Company (ZMC) have signed an exclusive agreement to manufacture and commercialise a novel broad-spectrum antibiotic called nemonoxacin in China.


The product is being developed as a treatment for respiratory infections and has already shown efficacy and safety in multinational clinical trials involving patients with community acquired pneumonia (CAP) and diabetic foot infections.


The once-daily treatment, which is available in both oral and intravenous formulations, is effective against methicillin-resistant and quinolone-resistant Staphylococcus aureus.


Under the terms of the 20-year agreement, Taiwanese company TaiGen will

Related News